SubHero Banner

Cabenuva (cabotegravir, rilpivirine), Vocabria (cabotegravir) – New drug approvals

January 21, 2021 - The FDA announced the approval of ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable ARV regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Download PDF